Navigation Links
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Date:6/26/2008

ve crisis.

Eli Lilly and Company and Boehringer Ingelheim

In November 2002, Eli Lilly and Company and Boehringer Ingelheim signed a long-term agreement to jointly develop and commercialize duloxetine hydrochloride. This partnership covers neuroscience indications in most countries outside of the United States and Japan, with few exceptions.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.co.uk.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit http://www.boehringer-ingelheim.co.uk.

Duloxetine for major depressive episodes is marketed by Lilly and Boehringer Ingelheim in all countries included in the partnership under the brand name Cymbalta, except for Greece, Italy and Spain. In Greece, Italy and Spain Lilly markets the product as Cymbalta and Boehring
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
3. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
4. XTENT Announces European Regulatory Update
5. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
6. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
7. European Unions CHMP Issues Positive Opinion on Sugammadex
8. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
9. PRoFESS(R) Results Announced at XVII European Stroke Conference
10. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
11. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... pleased to announce first quarter 2012 revenues of $210,635, ... The increase in revenues was driven by surgeries at ... using the Kelyniam Custom Skull Implant made from PEEK ... quarter with the new management and a full sales ...
... SNDY) is pleased to announce that the Company has successfully ... $570,000.  As a result, the Company expects to achieve a ... financials, and show significant reduction of its liabilities for the ... issued Preferred Stock valued at $10 per share in order ...
Cached Medicine Technology:Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012 2Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012 3Solos Endoscopy Reduces Liabilities by More than $570,000 2Solos Endoscopy Reduces Liabilities by More than $570,000 3
(Date:7/12/2014)... York, NY (PRWEB) July 12, 2014 ... steady growth over the past five years, buoyed by ... agricultural sector's supply management system. “Eggs are a relatively ... result, per capita egg consumption generally grows in line ... Industry Analyst Will McKitterick. Furthermore, demand for new specialty ...
(Date:7/12/2014)... 2014 The rise in the number ... new advanced network architectures to suit the upsurge. Virtualization ... with increasing cloud storage technologies. The data traffic has ... mobility devices. This has resulted in larger and more ... forces for the SDN market. , The North American ...
(Date:7/12/2014)... The "North American ... Market by Angioplasty Balloon (Plain/Old, Cutting), ... IVC Filter (Retrievable), Endovascular Stent Graft ... studies the major market drivers, restraints, ... Canada. , Browse 108 market data ...
(Date:7/12/2014)... The Security Analytics market is estimated to ... by 2019, at an expected CAGR of 9.7% for ... counter the increasing number of security breaches, continued line ... systems in organizations are enormous. Vendors in the security ... architecture to develop better and more secure systems. , ...
(Date:7/12/2014)... Melbourne, Australia (PRWEB) July 12, 2014 ... past five years, despite rising competition from international and ... compound annual 2.9% over the five years through 2014-15. ... with consumers demanding more gaming services. Rises in discretionary ... have spent more money on non-essential items such as ...
Breaking Medicine News(10 mins):Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4
... Failure by Sutter Medical Center Santa Rosa and Santa ... of county services fuels efforts to make ... SANTA ROSA, Calif., March 12 In the ... workers,at Santa Rosa Memorial Hospital -- already engaged in ...
... show whether an antidepressant is working , , TUESDAY, March ... biomarker for depression that could lead to a quick ... making headway against the disease. , "This may be ... co-author Mark Rasenick, director of the Interdisciplinary Neuroscience Program ...
... study in the,Journal of the American Medical Association ... Staphylococus aureus), a simple,skin or nasal swab, is ... for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and Nosocomial ... March 12, 2008)., The findings of the ...
... (NYSE:,WLP) announced today that senior management is scheduled to present at ... Healthcare Conference on March 13, 2008, ... Daylight Time (EDT);, -- Lehman Brothers ... March 19, 2008, at 10:15 a.m. EDT., All interested parties ...
... a good news, bad news situation. Some women who ... dont have cancer, they do have atypical hyperplasia -- ... someday. This happens to one-fourth of women undergoing breast ... risk. , In their quest to discover who is ...
... Zimmer Holdings, Inc.,(NYSE ZMH; SWX: ZMH), a leader in the ... upcoming investor,conferences:, -- March 18, 2008 -- Cowen,s ... Massachusetts, 8:00 a.m. Eastern Time -- March 19, 2008 ... Conference, Miami Beach, Florida, 8:30 a.m. Eastern Time, ...
Cached Medicine News:Health News:Santa Rosa Healthcare Workers Seek Accountability From Catholic Hospital System 2Health News:Scientists Spot Biochemical Sign of Depression 2Health News:Scientists Spot Biochemical Sign of Depression 3Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 2Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 3Health News:COX-2 expression is marker for cancer development in some benign breast biopsies 4
The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
The new XVG catheter is our highest power thrombectomy catheter designed for accessing distal anatomy. Utilizing proprietary Cross-Stream water jet technology, the XVG catheter removes thrombus quick...
Redel Connector 10 Pin...
... a non-fluoroscopic navigation system that tracks multiple ... Fred Wittkampf, Ph.D., and is being developed ... ,The LocaLisa system uses three ... around the heart to track catheters. Using ...
Medicine Products: